South San Francisco, CA, United States of America

Shuo-Yen Jack Lin

This inventor holds 2 USPTO granted patents. Top assignee: Genentech, Inc.. Active years: 2018-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shuo-Yen Jack Lin. Retrieved from https://idiyas.com/inventor/shuo-yen-jack-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shuo-Yen Jack Lin: Innovator in NSP4 Inhibitors

Introduction

Shuo-Yen Jack Lin is a prominent inventor based in South San Francisco, CA. He has made significant contributions to the field of biotechnology, particularly in the development of NSP4 inhibitors. With a total of 2 patents, his work is recognized for its potential impact on therapeutic methods.

Latest Patents

Shuo-Yen Jack Lin's latest patents focus on NSP4 inhibitors and methods of use. The inventions provide NSP4 inhibitors, such as anti-NSP4 antibodies, and outline methods for utilizing these inhibitors effectively. This innovative approach aims to advance treatment options in relevant medical fields.

Career Highlights

Lin is currently employed at Genentech, Inc., a leading biotechnology company known for its commitment to developing groundbreaking therapies. His role at Genentech allows him to collaborate with other experts in the field and contribute to significant advancements in medical research.

Collaborations

Some of his notable coworkers include Daniel Kirchhofer and Menno Van Lookeren Campagne. Their collaborative efforts enhance the research environment and foster innovation within the company.

Conclusion

Shuo-Yen Jack Lin's work in NSP4 inhibitors exemplifies the innovative spirit of modern biotechnology. His contributions are paving the way for new therapeutic methods that could benefit many patients in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…